"Designing Growth Strategies is in our DNA"

Ophthalmic Disease Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, & Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), & Regional Forecast, 2024-2032

Last Updated: January 20, 2025 | Format: PDF | Report ID: FBI100441

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 6.5% from 2024-2032

Unit

Value (USD billion)

Segmentation

By Drug Class

  • Anti-inflammatory
  • Anti-infectives
  • Anti-VEGF
  • Anti-glaucoma
    • Beta Blockers
    • Prostaglandins Analogs
    • Alpha Adrenergic Agonists
    • Carbonic Anhydrase Inhibitors
    • Combination Drugs
    • Others
  • Others

By Dosage Form

  • Solid
  • Liquid
  • Semisolid

By Disease Indication

  • Glaucoma
    • Open Angle Glaucoma
    • Angle Closure Glaucoma
    • Others
  • Dry Eye Disease
  • Retinal Diseases
    • Diabetic Macular Edema (DME)
    • Macular Degeneration (AMD)
    • Diabetic Retinopathy (DR)
    • Retinal Vein Occlusion (RVO)
    • Others
  • Allergy & Infections
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • 2019-2032
  • 2023
  • 2019-2022
  • 180
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase